Natera, Inc. $NTRA Position Trimmed by Allspring Global Investments Holdings LLC

Key Points

• Allspring Global Investments cut its Natera stake by 18.9% in the third quarter, selling 78,151 shares and retaining 336,178 shares worth about $137.3 million. Institutional investors and hedge funds collectively own 99.9% of the stock.
• Natera’s third-quarter revenue increased 34.1% year over year to about $794 million, beating estimates, but its loss of $0.42 per share was wider than analysts expected. The company also raised its fiscal 2026 sales outlook.
• JPMorgan lowered its price target to $405 from $460 while maintaining an Overweight rating; analysts overall have a “Moderate Buy” consensus and an average target of $391.69. The article also cites CEO Steve Chapman’s planned departure as a source of uncertainty.

Allspring Global Investments Holdings LLC reduced its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 18.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 336,178 shares of the medical research company's stock after selling 78,151 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.23% of Natera worth $137,319,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC raised its position in Natera by 0.4% during the 3rd quarter. Brighton Jones LLC now owns 11,442 shares of the medical research company's stock worth $4,729,000 after buying an additional 51 shares during the last quarter. Ethic Inc. boosted its holdings in shares of Natera by 30.3% in the third quarter. Ethic Inc. now owns 1,835 shares of the medical research company's stock valued at $759,000 after acquiring an additional 427 shares in the last quarter. Pictet Asset Management Holding SA boosted its holdings in shares of Natera by 9.9% in the third quarter. Pictet Asset Management Holding SA now owns 55,946 shares of the medical research company's stock valued at $23,123,000 after acquiring an additional 5,022 shares in the last quarter. AlphaCentric Advisors LLC increased its stake in shares of Natera by 3.0% during the third quarter. AlphaCentric Advisors LLC now owns 1,432 shares of the medical research company's stock worth $592,000 after acquiring an additional 42 shares during the period. Finally, Parallel Advisors LLC increased its stake in shares of Natera by 6.9% during the third quarter. Parallel Advisors LLC now owns 971 shares of the medical research company's stock worth $401,000 after acquiring an additional 63 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794 million, beating analyst expectations. Natera also raised its fiscal 2026 sales outlook, supporting the growth outlook for its testing business. Natera Q3 results and outlook
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could broaden access to the cancer-monitoring test and support adoption. Medicare coverage for Signatera in HCC
• Neutral Sentiment: JPMorgan lowered its price target from $460 to $405 but maintained an Overweight rating, indicating continued confidence while marking down its valuation expectations. JPMorgan price-target update
• Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition. The announcement weighed on sentiment despite the stronger revenue outlook. CEO transition and market reaction
• Negative Sentiment: The quarterly per-share loss was wider than analysts expected (about $0.42 versus a $0.28 consensus loss), despite revenue beating estimates. This earnings miss appears to have contributed to the selloff. Natera third-quarter financial results

Natera Price Performance

Shares of NTRA opened at $310.67 on Monday. The company has a 50-day simple moving average of $380.25 and a 200-day simple moving average of $269.68. The company has a market capitalization of $44.78 billion, a PE ratio of -272.52 and a beta of 1.55. Natera, Inc. has a 52-week low of $181.00 and a 52-week high of $437.41.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.14). The company had revenue of $793.98 million during the quarter, compared to analyst estimates of $707.54 million. Natera had a negative net margin of 5.66% and a negative return on equity of 8.73%. The firm's revenue for the quarter was up 34.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.64) EPS. On average, research analysts anticipate that Natera, Inc. will post -1.14 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on NTRA shares. Leerink Partners set a $330.00 price target on shares of Natera in a report on Friday, August 7th. Roth Capital began coverage on Natera in a report on Thursday, October 22nd. They issued a "buy" rating and a $475.00 price objective on the stock. Zacks Research cut Natera from a "hold" rating to a "strong sell" rating in a research report on Friday, October 16th. JPMorgan Chase & Co. cut their target price on Natera from $460.00 to $405.00 and set an "overweight" rating for the company in a research note on Friday. Finally, Wells Fargo & Company increased their target price on Natera from $220.00 to $284.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Natera has an average rating of "Moderate Buy" and an average price target of $391.69.

Insider Buying and Selling at Natera

In other news, CEO Steven Chapman sold 3,801 shares of the business's stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $411.80, for a total transaction of $1,565,251.80. Following the sale, the chief executive officer owned 87,431 shares of the company's stock, valued at $36,004,085.80. The trade was a 4.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 15,160 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total value of $4,955,652.40. Following the sale, the insider directly owned 110,859 shares in the company, valued at $36,238,698.51. This trade represents a 12.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 47,056 shares of company stock valued at $17,760,989. Corporate insiders own 5.05% of the company's stock.

Natera Profile

Natera, Inc is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring.

In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

The company also provides Prospera, a molecular test used to help assess organ transplant rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.